ChromaDex (NASDAQ: CDXC) reported Q4 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $12.91 million.

Fourth Quarter 2019 Highlights vs. Fourth Quarter 2018

• Strong growth in net sales to $13.1 million, higher gross margins, and significantly improved marketing efficiency year-over-year.
• Tru Niagen® net sales of $10.2 million, a 57% increase year-over-year.
• Net loss per share of ($0.15) as reported, or non-GAAP net loss per share of ($0.11) excluding a $0.04 per share charge related to the non-cash write-off of Elysium receivable as bad debt expense.
• Expanded distribution rights with Matakana in Australia and secured partnership with a leading health and beauty retailer to launch in over 200 U.K. stores in 2020.

“We delivered strong performance across key metrics in 2019, secured regulatory approval in the EU and Australia, and published the sixth human clinical study demonstrating the safety and efficacy of Niagen,” said ChromaDex CEO Rob Fried. “By achieving these commercial, regulatory, and scientific milestones, we continue to make great progress against our financial and strategic goals.”

2020 Outlook

Looking forward, the Company expects revenue growth to be driven primarily by its U.S. ecommerce and Watsons international business, as well as the launch of Tru Niagen with other partners and distributors in new international markets, including U.K. and Australia, and new platforms, including Persona Nutrition, which was recently acquired by Nestlé Health Science. The Company expects continued gross margin improvement driven by a higher mix of Tru Niagen sales, product design changes implemented in late 2019, and additional supply chain cost savings initiatives in 2020. The Company expects lower selling, marketing and advertising as well as general and administrative expenses as a percentage of net sales driven by strong growth from returning customers and scale on our fixed overhead costs driven by organizational realignment initiatives, as well as new systems and processes.

For earnings history and earnings-related data on ChromaDex (CDXC) click here.